Published in Pediatr Nephrol on March 14, 2017
Strict blood-pressure control and progression of renal failure in children. N Engl J Med (2009) 5.71
Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. N Engl J Med (2015) 4.78
[Intercapillary deposits of IgA-IgG]. J Urol Nephrol (Paris) (1968) 4.44
Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet (1999) 3.51
Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet (2011) 3.15
IgA nephropathy. N Engl J Med (2013) 2.96
Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest (2009) 2.82
Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest (1999) 2.77
Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol (2008) 2.48
Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol (2004) 2.48
Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol (2004) 2.47
Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant (2009) 2.27
The pathophysiology of IgA nephropathy. J Am Soc Nephrol (2011) 2.27
IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest (2008) 2.15
The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int (2010) 2.14
Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus. J Clin Invest (1980) 2.11
Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. Kidney Int (2001) 1.99
Podocytopenia and disease severity in IgA nephropathy. Kidney Int (2002) 1.98
The changing pattern of adult primary glomerular disease. Nephrol Dial Transplant (2009) 1.90
Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int (2004) 1.78
A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy. Nat Genet (2011) 1.77
Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet (2014) 1.74
Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol (2006) 1.72
Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol (2010) 1.70
Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet (2012) 1.69
A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med (1990) 1.68
Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study. J Am Soc Nephrol (2015) 1.68
IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy. Semin Nephrol (2008) 1.64
HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol (2010) 1.64
Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol (2002) 1.62
A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. J Am Soc Nephrol (1999) 1.60
Randomized Controlled Trial of Mycophenolate Mofetil in Children, Adolescents, and Adults With IgA Nephropathy. Am J Kidney Dis (2015) 1.49
Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol (2001) 1.41
Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol (2012) 1.40
The Italian experience of the national registry of renal biopsies. Kidney Int (2004) 1.38
Familial IgA nephropathy. Evidence of an inherited mechanism of disease. N Engl J Med (1985) 1.38
Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med (2001) 1.35
Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis (2014) 1.35
The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant (2010) 1.34
The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int (2012) 1.31
Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther (2012) 1.31
Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol (2012) 1.30
A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant (2014) 1.29
Current therapy for IgA nephropathy. J Am Soc Nephrol (2011) 1.28
The changing spectrum of primary glomerular diseases within 15 years: a survey of 3331 patients in a single Chinese centre. Nephrol Dial Transplant (2008) 1.25
Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol (2006) 1.24
Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study. J Am Soc Nephrol (2013) 1.20
Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of IgA nephropathy. Kidney Blood Press Res (2008) 1.18
The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease. Clin J Am Soc Nephrol (2013) 1.17
Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy. Nephrol Dial Transplant (2008) 1.16
Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant (2005) 1.13
Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int (2009) 1.11
Variants in Complement Factor H and Complement Factor H-Related Protein Genes, CFHR3 and CFHR1, Affect Complement Activation in IgA Nephropathy. J Am Soc Nephrol (2014) 1.11
Japan Renal Biopsy Registry: the first nationwide, web-based, and prospective registry system of renal biopsies in Japan. Clin Exp Nephrol (2011) 1.08
Familial clustering of IgA nephropathy: further evidence in an Italian population. Am J Kidney Dis (1999) 1.06
New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int (2015) 1.04
Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int (2005) 1.03
Pediatric IgA nephropathy: clinical and therapeutic perspectives. Semin Nephrol (2008) 1.01
Intraspecies heterogeneity of immunoglobulin alpha-chain constant region genes in rhesus macaques. Immunology (2001) 1.00
[A randomized control trial of mycophenolate mofeil treatment in severe IgA nephropathy]. Zhonghua Yi Xue Za Zhi (2002) 0.99
Histological differences in new-onset IgA nephropathy between children and adults. Nephrol Dial Transplant (2006) 0.96
Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev (2015) 0.91
Polymeric IgA1 from patients with IgA nephropathy upregulates transforming growth factor-beta synthesis and signal transduction in human mesangial cells via the renin-angiotensin system. J Am Soc Nephrol (2003) 0.91
Clinicopathological features and the prognosis of IgA nephropathy in Japanese children on long-term observation. Clin Nephrol (2005) 0.91
Treatment of IgA nephropathy and Henoch-Schönlein nephritis. Nat Rev Nephrol (2013) 0.90
Long-term results of a randomized controlled trial in childhood IgA nephropathy. Clin J Am Soc Nephrol (2011) 0.89
Histology and immunohistology of IgA nephropathy. J Nephrol (2005) 0.89
Abnormalities of the IgA immune system in members of unrelated pedigrees from patients with IgA nephropathy. Clin Exp Immunol (1993) 0.88
Characterization of a large Lebanese family segregating IgA nephropathy. Nephrol Dial Transplant (2006) 0.87
Changes in Proteinuria and Side Effects of Corticosteroids Alone or in Combination with Azathioprine at Different Stages of IgA Nephropathy. Clin J Am Soc Nephrol (2016) 0.86
Role of complement in IgA nephropathy. J Nephrol (2015) 0.85
ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials. Int J Clin Pract (2009) 0.83
A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction. J Am Soc Nephrol (2016) 0.81
Familial cases of Berger's disease and anaphylactoid purpura: more frequent than previously thought. Am J Med (1989) 0.81
Treatment of severe IgA nephropathy: mycophenolate mofetil/prednisone compared to cyclophosphamide/prednisone. Int J Clin Pharmacol Ther (2014) 0.79
Comparison of steroid-pulse therapy and combined with mizoribine in IgA nephropathy: a randomized controlled trial. Clin Exp Nephrol (2016) 0.78
Proteinuria during Follow-Up Period and Long-Term Renal Survival of Childhood IgA Nephropathy. PLoS One (2016) 0.78
Tonsillectomy in a European Cohort of 1,147 Patients with IgA Nephropathy. Nephron (2015) 0.78
Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy. Nephrol Dial Transplant (2008) 0.78
Spleen Tyrosine Kinase: A Crucial Player and Potential Therapeutic Target in Renal Disease. Nephron (2016) 0.78
N-acetylgalactosaminide α2,6-sialyltransferase II is a candidate enzyme for sialylation of galactose-deficient IgA1, the key autoantigen in IgA nephropathy. Nephrol Dial Transplant (2014) 0.77
The effect of calcineurin inhibitors in the treatment of IgA nephropathy: A systematic review and meta-analysis (PRISMA). Medicine (Baltimore) (2016) 0.77
Investigations of Glucocorticoid Action in GN. J Am Soc Nephrol (2016) 0.77
Corticosteroid Treatment Influences TA-Proteinuria and Renal Survival in IgA Nephropathy. PLoS One (2016) 0.75
Rapidly progressive IgA nephropathy: a form of vasculitis or a complement-mediated disease? Clin Kidney J (2015) 0.75
Discordant clinicopathological features in monozygotic twins with IgA nephropathy. Nephrol Dial Transplant (2011) 0.75
[Annual incidence of glomerulonephritis in the extended Rhône-Alpes region in 1987-1988]. Presse Med (1990) 0.75